Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04PMS
|
|||
| Former ID |
DNCL002732
|
|||
| Drug Name |
HER2 antigen-specific cancer immunotherapeutic
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | |
| Company |
GlaxoSmithKline
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01220128) Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.